ARCA biopharma, Inc. (ABIO)
| Previous Close | 2.1900 |
| Open | 2.2600 |
| Bid | 2.1800 x 1000 |
| Ask | 2.1900 x 1000 |
| Day's Range | 2.1800 - 2.2600 |
| 52 Week Range | 1.7600 - 2.7000 |
| Volume | |
| Avg. Volume | 39,786 |
| Market Cap | 31.414M |
| Beta (5Y Monthly) | 1.86 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.0670 |
| Earnings Date | Mar 13, 2023 - Mar 17, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
James Flynn Joins ARCA biopharma Board of Directors
WESTMINSTER, Colo., Dec. 19, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that James Flynn has joined its Board of Directors. “We are pleased to welcome James Flynn to our Board,” said Robert E. Conway, Chairman of ARCA’s Board of Directors. “We appreciate his participation and input on the Company’s Board of Directors, including our process for evaluating strategic options for the Company.” Mr. Flynn is currently a Managing Member and Portfolio Manager of Nerium
- Simply Wall St.
One ARCA biopharma, Inc. (NASDAQ:ABIO) insider upped their stake by 5,155% in the previous year
Viewing insider transactions for ARCA biopharma, Inc.'s ( NASDAQ:ABIO ) over the last year, we see that insiders were...
- GlobeNewswire
ARCA biopharma Announces Third Quarter 2022 Financial Results
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic optionsWESTMINSTER, Colo., Oct. 28, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported third quarter 2022 financial results and provided a corporate update. In May 2022, the Company retaine
